advertisement
Advances in Therapy 24
Showing records 1 to 24 | Display all abstracts in Advances in Therapy69393 Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study
Kawase K
Advances in Therapy 2016; 33: 1612-1627
69177 Latanoprost and Dorzolamide for the Treatment of Pediatric Glaucoma: The Glaucoma Italian Pediatric Study (Gipsy), Design and Baseline Characteristics
Quaranta L
Advances in Therapy 2016; 33: 1305-1315
69364 Additive Intraocular Pressure Lowering Effects of the Rho Kinase Inhibitor, Ripasudil in Glaucoma Patients Not Able to Obtain Adequate Control After Other Maximal Tolerated Medical Therapy
Sato S
Advances in Therapy 2016; 33: 1628-1634
69287 Effects of Brinzolamide, a Topical Carbonic Anhydrase Inhibitor, on Corneal Endothelial Cells
Nakano T
Advances in Therapy 2016; 33: 1452-1459
69364 Additive Intraocular Pressure Lowering Effects of the Rho Kinase Inhibitor, Ripasudil in Glaucoma Patients Not Able to Obtain Adequate Control After Other Maximal Tolerated Medical Therapy
Hirooka K
Advances in Therapy 2016; 33: 1628-1634
69393 Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study
Vittitow JL
Advances in Therapy 2016; 33: 1612-1627
69287 Effects of Brinzolamide, a Topical Carbonic Anhydrase Inhibitor, on Corneal Endothelial Cells
Inoue R
Advances in Therapy 2016; 33: 1452-1459
69177 Latanoprost and Dorzolamide for the Treatment of Pediatric Glaucoma: The Glaucoma Italian Pediatric Study (Gipsy), Design and Baseline Characteristics
Biagioli E; Galli F
Advances in Therapy 2016; 33: 1305-1315
69364 Additive Intraocular Pressure Lowering Effects of the Rho Kinase Inhibitor, Ripasudil in Glaucoma Patients Not Able to Obtain Adequate Control After Other Maximal Tolerated Medical Therapy
Nitta E
Advances in Therapy 2016; 33: 1628-1634
69287 Effects of Brinzolamide, a Topical Carbonic Anhydrase Inhibitor, on Corneal Endothelial Cells
Kimura T
Advances in Therapy 2016; 33: 1452-1459
69393 Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study
Weinreb RN
Advances in Therapy 2016; 33: 1612-1627
69287 Effects of Brinzolamide, a Topical Carbonic Anhydrase Inhibitor, on Corneal Endothelial Cells
Suzumura H
Advances in Therapy 2016; 33: 1452-1459
69177 Latanoprost and Dorzolamide for the Treatment of Pediatric Glaucoma: The Glaucoma Italian Pediatric Study (Gipsy), Design and Baseline Characteristics
Poli D
Advances in Therapy 2016; 33: 1305-1315
69393 Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study
Araie M
Advances in Therapy 2016; 33: 1612-1627
69364 Additive Intraocular Pressure Lowering Effects of the Rho Kinase Inhibitor, Ripasudil in Glaucoma Patients Not Able to Obtain Adequate Control After Other Maximal Tolerated Medical Therapy
Ukegawa K
Advances in Therapy 2016; 33: 1628-1634
69287 Effects of Brinzolamide, a Topical Carbonic Anhydrase Inhibitor, on Corneal Endothelial Cells
Tanino T
Advances in Therapy 2016; 33: 1452-1459
69177 Latanoprost and Dorzolamide for the Treatment of Pediatric Glaucoma: The Glaucoma Italian Pediatric Study (Gipsy), Design and Baseline Characteristics
Rulli E
Advances in Therapy 2016; 33: 1305-1315
69393 Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study
Advances in Therapy 2016; 33: 1612-1627
69364 Additive Intraocular Pressure Lowering Effects of the Rho Kinase Inhibitor, Ripasudil in Glaucoma Patients Not Able to Obtain Adequate Control After Other Maximal Tolerated Medical Therapy
Tsujikawa A
Advances in Therapy 2016; 33: 1628-1634
69177 Latanoprost and Dorzolamide for the Treatment of Pediatric Glaucoma: The Glaucoma Italian Pediatric Study (Gipsy), Design and Baseline Characteristics
Riva I
Advances in Therapy 2016; 33: 1305-1315
69287 Effects of Brinzolamide, a Topical Carbonic Anhydrase Inhibitor, on Corneal Endothelial Cells
Yamazaki Y
Advances in Therapy 2016; 33: 1452-1459
69177 Latanoprost and Dorzolamide for the Treatment of Pediatric Glaucoma: The Glaucoma Italian Pediatric Study (Gipsy), Design and Baseline Characteristics
Hollander L
Advances in Therapy 2016; 33: 1305-1315
69287 Effects of Brinzolamide, a Topical Carbonic Anhydrase Inhibitor, on Corneal Endothelial Cells
Yoshikawa K; Tatemichi M
Advances in Therapy 2016; 33: 1452-1459
69177 Latanoprost and Dorzolamide for the Treatment of Pediatric Glaucoma: The Glaucoma Italian Pediatric Study (Gipsy), Design and Baseline Characteristics
Katsanos A; Longo A; Uva MG; Torri V; Weinreb RN
Advances in Therapy 2016; 33: 1305-1315